Research Artcle Ment Health Fam Med (2018) 14: 748-756 2018 Mental Health and Family Medicine Ltd Safety of Disclosing Amyloid Imaging Results to MCI and AD Patients Carl Taswell Brain Health Alliance, Ladera Ranch, CA, USA and Department of Psychiatry, University of California San Diego, La Jolla, CA, USA Cheryl Donohue Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia Maree T. Mastwyk Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia Andrea G. Louey Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia Jacqueline Giummarra Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia Joanne Robertson Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia David G. Darby Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia Colin L. Masters Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia Christopher C. Rowe Florey Inst Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia and Austn Health Dept Molecular Imaging, Melbourne, VIC, Australia ABSTRACT Objective: To assess the psychological impact of disclosing a positive or negative amyloid brain scan result to symptomatic individuals with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD). Design: Prospective longitudinal cohort study. Setting: Florey Institute of Neuroscience & Mental Health, University of Melbourne, Australia. Participants: A total of 133 individuals aged 50–85 with MCI or mild AD enrolled in the study with data collected between October 2014 and June 2016. Interventions: Disclosure of amyloid imaging results to participants. Measurements: Positron emission tomography (PET) brain amyloid imaging with [18F]-NAV4694; psychometric scales including the Center for Epidemiologic Studies Depression (CES-D) scale, Geriatric Depression Scale (GDS), Hospital Anxiety and Depression Scales (HADS-A and HADS-D) and State-Trait Anxiety Inventory (STAI) performed before and after disclosure of amyloid imaging results. Results: We did not observe any worsening of psychological health with a panel of psychometric scales assessed on individuals to whom amyloid brain scan results were disclosed. Conclusions: We consider it safe, without apparent risk of harm to patients, to disclose amyloid imaging results to patients who have no prior history of neuropsychiatric illness. Keywords: Alzheimer’s disease, Dementia, Mild cognitive impairment, PET scan, Brain amyloid imaging, Risk disclosure